C9492 Durvalumab - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Durvalumab

Brand Name:

Imfinzi

Strength:

10 mg

HCPCS:

C9492

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Checkpoint Inhibitor

Minor Drug Class:

PD-L1

Oral (Y/N):

No

FDA Approval Year:

2017

FDA Discontinuation Year:

CMS Effective Date:

Oct. 1, 2017

CMS Discontinuation Date:

Status:

In Use